Cholesterol-lowering drugs and Alzheimer's disease

Future Lipidology

Volumn 2, Issue 4, 2007, Pages 423-432

  Eckert, Gunter P ^a   Müller, Walter E ^a   Wood, W Gibson ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Brain; Cholesterol; Statins

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOSOME; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; HUMAN; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; ISCHEMIC HEART DISEASE; LIPID BRAIN LEVEL; LONG TERM CARE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE DRUG DOSE;

EID: 34547860418     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.2.4.423     Document Type: Review

References (90)

1. Hamelin BA, Turgeon J: Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19, 26-37 (1998).
2. Lousberg TR, Denham AM, Rasmussen JR: A comparison of clinical outcome studies among cholesterol-lowering agents. Ann. Pharmacother. 35(12), 1599-1607 (2001).
3. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84(3), 413-428 (1999).
4. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM, 10. Proc, Natl Acad. Sci. USA 98(10), 5815-5820 (2001).
5. Schachter M: Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19(1), 117-125 (2005).
6. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80(6), 565-581 (2006).
7. Botti RE, Triscari J, Pan HY, Zayatt J: Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin. Neuropharmacol. 14(3), 256-261 (1991).
8. Johnson-Anuna LN, Eckert GP, Keller JH et al.: Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J. Pharmacol. Exp. Ther. 312(2), 796-793 (2005).
9. Thelen, KM, Rentsch KM, Gutteck U et al.: Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther. 316(3), 1146-1152 (2005).
10. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA: Molecular pathways to neurodegeneration. Nat. Med. 10(Suppl.), S2-S9 (2004).
11. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580), 353-356 (2002).
12. Michikawa M: The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid betaprotein and cholesterol. Mol. Neurobiol. 27(1), 1-12 (2003).
13. Wood WG, Eckert GP. Igbavboa U, Müller WE: Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim. Biophys. Acta 1610(2), 281-290 (2003).
14. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM: The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10(8), 1699-1705 (1999).
15. Bodovitz S, Klein WI: Cholesterol modulates alpha-secretese cleavage of amyloid precursor protein. J. Biol, Chem. 271(8), 4436-4440 (1996).
16. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95(11), 6460-6464 (1998).
17. Fassbender K, Simons M, Bergmann C et al.: Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98(10), 5856-5861 (2001).
18. Wolozin B: A fluid connection: cholesterol and Abeta. Proc. Natl Acad. Sci. USA 98(10), 5371-5373 (2001).
19. Buxbaum JD, Geoghagen NS, Friedhoff LT: Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J. Alzheimers Dis. 3(2), 221-229 (2001).
20. Parvathy S, Ehrlich M, Pedrini S et al.: Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J. Neurochem. 90(4), 1005-1010 (2004).
21. Kirsch C, Eckert GP, Müller WE: Statins affect cholesterol micro-domains in brain plasma membranes. Biochem. Pharmacol. 65(5), 843-856 (2003).
22. Burns MP, Igbavboa U, Wang L, Wood WG, Duff K: Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. Neuromolecular. Med. 8(3), 319-328 (2006).
23. Gong JS, Sawamura N, Zou K, Sakai J, Yanagisawa K, Michikawa M: Amyloid beta-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. J. Neurosci. Res. 70(3), 439-446 (2002).
24. Igbavboa U, Pidcock JM, Johnson LN et al.: Cholesterol distribution in the Golgi complex of DITNC1 astrocytes is differentially altered by fresh and aged amyloid beta-peptide-(1-42). J. Biol. Chem. 278(19), 17150-17157 (2003).
25. Refolo LM, Pappolla MA, Malester B et al.: Hypercholesterolemia accelerates the alzheimer's amyloid pathology in a transgenic mouse model. Nerobiol. Dis. 7(4), 321-331 (2000).
26. Sparks DL, Scheff SW, Hunsaker JC, Liu H, Landers T, Gross DR: Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126(1), 88-94 (1994).
27. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC: Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13(4), 455-459 (2002).
28. Howland DS, Trusko SP, Savage MJ et al.: Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J. Biol. Chem. 273, 16576-16582 (1998).
29. Dietschy JM, Turley SD: Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45(8), 1375-1397 (2004).
30. Eckert GP, Kirsch C. Müller WE: Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice. Neuroreport 12(5), 883-887 (2001).
31. Kirsch C, Eckert GP, Koudinov AR, Muller WE: Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry 36 (Suppl. 2), S113-S119 (2003).
32. Kalaria RN: The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann. NY Acad Sci. 893, 113-125 (1999).
33. Dietschy JM, Turley SD: Control of cholesterol turnover in the mouse. J. Biol. Chem. 277(6), 3801-3804 (2002).
34. Kraute BR, Princen HM: Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis 140(1), 15-24 (1998).
35. Kea T, Brown MS, Goldstein JL: Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J. Clin. Invest. 66(5), 1094-100 (1980).
36. Kirsch C, Eckert GP, Müller WE: Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem. Pharmacol. 65, 843-856 (2003).
37. Petanceska SS, DeRosa S, Olm V et al.: Statin therapy for Alzheimer's disease: will it work? J. Mol. Neurosci. 19(1-2), 155-161 (2002).
38. Park IH, Hwang EM, Hong HS et al.: Lovastatin enhances Abeta production and senile plague deposition in female Tg2576 mice. Neurobiol. Aging 24(5), 637-643 (2003).
39. Li L, Cao D, Wan H, Chen J: Enhancement of learning and memory by statins beyond Alzheimer's disease. Neurobiol. Aging 25(S2), 82 (2004).
40. Pappolla MA, Bryant-Thomas T, Herbert D et al.: Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61, 199-205 (2003).
41. Knittweis JW, McMullen WA: The effect of apoE on dementia is not through atherosclerosis: The Rotterdam Study: To the Editor. Neurology 54, 2356-2358 (2000).
42. Kuo Y-M, Emmerling MR. Bisgaier CL et al.: Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Ab 1-42 levels. Biochem. Biophys. Res. Commun. 252, 711-715 (1998).
43. Romas SN, Tang MX, Berglund L, Mayeux R: ApoE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53, 517-521 (1999).
44. Evans RM, Emsley CL, Gao S et al.: Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54, 240-242 (2000).
45. Kivipelto M, Helkala E-L, Laakso MP et al.: Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal population based study. BMJ 322, 1447-1451 (2001).
46. Launer LJ, White LR, Petrovitsch H, Ross GW, Curb JD: Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology, 57, 1447-1452 (2001).
47. Tan ZS, Seshadri S, Beiser A et al.: Plasma total cholesterol level as a risk factor for Alzheimer disease. Arch. Int. Med. 163, 1053-1057 (2003).
48. Hebert LE, Scherr PA, Bieniss JL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60(8), 1119-1122 (2003).
49. CDC™/National Health and Nutrition Examination Survey (NCHS): Cholesterol status among adults in the United States. (2003).
50. Mielke MM, Zandi, PP, Sjogren M et al.: High total cholesterol levels in late life associated with,a reduced risk of dementia. Neurology 64(10), 1689-1695 (2005).
51. Mason RP, Shoemaker WJ, Shajonko L., Chambers TE, Herbette LG: Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 13, 413-419 (1992).
52. Sparks DL: Coronary artery disease, hypertension, apoE, and cholesterol: A link to Alzheimers disease? Ann. NY Acad. Sci. 826, 128-146 (1997).
53. Eckert GP, Cairns NJ, Maras A, Gattaz WF, Müller WE: Cholesterol modulates the membrane disordering effects of β-amyloid peptides in the hippocampus: Specific changes in Alzheimer's disease. Dement Geriatr. Cogn. Disord. 11, 181-186 (2000).
54. Heverin M, BogdanovicN, Lurjohann D et al.: Changes in the Levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 45, 186-193 (2004).
55. Mulder M, Ravid R, Swaab DF et al.: Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis. Assoc. Disorders 12, 198-203 (1998).
56. Demeester N, Castro G, Desrumaux C et al.: Characterization and functional studies of lipoproteins, lipid transfer proteins and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J. Lipid Res. 41, 963-974 (2000).
57. Wollmer MA, Streffer JR, Lütjohann D et al: ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 5757, 1-6 (2002).
58. Papassotiropoulos A, Lutjohann D, Bagli M et al.: 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36, 27-32 (2002).
59. Wood WG, Schroeder F, Avdulov NA, Chochina SV, Igbavboa U: Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease. Lipids 34(3), 225-234 (1999).
60. Igbavboa U, Avdulov NA, Chochina SV, Wood WG: Transbilayer distribution of cholesterol is modified in brain synaptic plasma membranes of knockout mice deficient in the low density lipoprotein receptor, apolipoprotein E, or both proteins. J. Neurochim. 69, 1661-1667 (1997).
61. Hayashi H, Igbavboa U, Hamanaka H et al.: Cholesterol is increased in the exofacial leafler of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport 13, 383-386 (2002).
62. Igbavboa U, Avdulov NA, Schroeder F, Wood WG: Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J. Neurochem. 66, 1717-1725 (1996).
63. Lee S-J, Liyanage U, Bickel PE, Xia W, Lansbury PT, Kosik KS: A detergent-insoluble membrane compartment contains amyloid-beta in vivo. Nat. Med. 4, 730-734 (1998).
64. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Haltzman DM: Human and murine apoE markedly alters Ab metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9, 305-318 (2002).
65. Morishima-Kawashima M, Ihara Y: The presence of amyloid b-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 37, 15247-15253 (1998).
66. Yamamoto N, Igbabvoa U, Shimada Y et al.: Accelerated Abeta aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett. 569(1-3), 135-139 (2004).
67. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443 (2000).
68. Jick H, Zomberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 356(9242), 1627-1631 (2000).
69. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer, GP: The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J. Gerontol. A Biol. Sci. Med. Sci. 57(7), M414-M418 (2002).
70. Fassbender K, Stroick M, Bertsch T. et al.: Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59(8), 1257-1258 (2002).
71. Vega GL, Weiner MF, Lipton AM et al.: Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch. Neurol. 60,(4) 510-515 (2003).
72. Locatelli S, Lutjohann D, Schmidt HH, Otto C, Beisiegel U, von Bergmann K: Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch. Neurol. 59(2), 213-216 (2002).
73. Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD: Treatment with controlled-release lovastatin decreases serum concentrations of human β-amyloid (A β) Peptide. Int. J. Neuropsychopharmacol. 4(2), 127-130 (2001).
74. Simons M, Schwarzler F, Lutjohann D et al.: Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52(3), 346-350 (2002).
75. Rea TD, Breitner JC, Peaty BM et al.: Statin use and the risk of incident dementia - The cardiovascular health study. Arch. Neurol. 62(7), 1047-1051 (2005).
76. Zamrini E, McGwin G, Roseman JM: Association between statin use and Alzheimer's disease. Neuroepidemiology 23(1-2), 94-98 (2004).
77. Li G, Higdon R, Kukull WA et al.: Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 65(9), 1624-1628 (2004).
78. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M: Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J. Am. Geriatr. Soc. 50(11), 1852-1856 (2002).
79. Rockwood K, Kirkland S, Hogan DB et al.: Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59(2), 223-227 (2002).
80. Zandi PP, Sparks, DL, Khachaturian AS et al.: Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry 62(2), 217-224 (2005).
81. Zhou B, Teramukai S, Fukushima M: Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. dement. Geriatr. Cogn. Disord. 23(3), 194-201 (2007).
82. Rockwood K: Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol. Scand. Suppl. 185, 71-77 (2006).
83. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 356, 1627-1631 (2000).
84. Rockwood K, Kirkland S, Hogan DB et al.: Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59, 223-227 (2002).
85. Werner N, Nickenig G, Laufs U: Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res. Cardiol. 97, 105-116 (2002).
86. Mcfarlane SI, Muniyappa R, Francisco R, Sowers JR: Pleiotropic effects of statins: Lipid reduction and beyond. J. Clin. Endocrinol. Metab. 87, 1451-1458 (2002).
87. Cole SL, Grudzien A, Manhart I, Kelly B, Oakley H, Vassar R: A tale of two statins: the effects of lovastatin and simvastatin on APP metabolism. Neurobiol. Aging 25 (S2), 77 (2004).
88. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME Gandy S: Modulation of statin-activated shedding of alzheimer APP ectodomain by ROCK. PLoS. Med. 2(1), e18 (2005).
89. Johnson-Anuna LN, Eckert GP, Franke C, Igbavboa U, Muller WE, Wood WG: Simvastatin protects neurons from cytotoxicity by up-regulathig Bcl-2 mRNA and protein. J. Neurochem. 101(1), 77-86 (2007).
90. Franke C, Nöldner M, Abdel-Kader R et al.: Bcl-2 upregulation and neuroprotection in guine pig brain following chronic simvastatin treatment. Neurobiol. Dis. 25(2), 438-445 (2007).